(IRMD) Iradimed - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US46266A1097

MRI Pumps, Monitors, Detectors, Poles

IRMD EPS (Earnings per Share)

EPS (Earnings per Share) of IRMD over the last years for every Quarter: "2020-03": 0.14, "2020-06": -0.17, "2020-09": 0.09, "2020-12": 0.05, "2021-03": 0.11, "2021-06": 0.12, "2021-09": 0.2, "2021-12": 0.31, "2022-03": 0.2, "2022-06": 0.26, "2022-09": 0.27, "2022-12": 0.29, "2023-03": 0.27, "2023-06": 0.33, "2023-09": 0.4, "2023-12": 0.36, "2024-03": 0.32, "2024-06": 0.38, "2024-09": 0.4, "2024-12": 0.4, "2025-03": 0.37,

IRMD Revenue

Revenue of IRMD over the last years for every Quarter: 2020-03: 8.677541, 2020-06: 6.794692, 2020-09: 7.699096, 2020-12: 8.546043, 2021-03: 9.223996, 2021-06: 9.810423, 2021-09: 10.907302, 2021-12: 11.87286, 2022-03: 12.31071, 2022-06: 12.721569, 2022-09: 13.407272, 2022-12: 14.863594, 2023-03: 15.475083, 2023-06: 16.130396, 2023-09: 16.50464, 2023-12: 17.452176, 2024-03: 17.598119, 2024-06: 17.928876, 2024-09: 18.325959, 2024-12: 19.389167, 2025-03: 19.510637,

Description: IRMD Iradimed

Iradimed Corporation is a leading provider of innovative medical devices designed for compatibility with magnetic resonance imaging (MRI) systems, catering to a global customer base. The companys product portfolio encompasses a range of MRI-compatible solutions, including infusion pump systems, patient vital signs monitoring systems, and ferromagnetic detection devices, as well as associated accessories and disposables. By serving hospitals, acute care facilities, and outpatient imaging centers through a multi-channel sales approach, Iradimed has established itself as a significant player in the healthcare equipment sector.

With a strong foundation in research and development, Iradimed has expanded its offerings to include non-magnetic IV poles, wireless remote displays and controls, and advanced monitoring systems. The companys commitment to delivering high-quality, reliable products has enabled it to build a loyal customer base and drive growth. As a publicly traded company listed on NASDAQ under the ticker symbol IRMD, Iradimed is well-positioned to capitalize on emerging trends in the healthcare industry.

Analyzing the technical data, we observe that IRMDs stock price has been trending upward, with a current price of 58.24 and a 20-day SMA of 57.72, indicating a stable short-term outlook. The 50-day and 200-day SMAs at 54.51 and 53.38, respectively, suggest a longer-term uptrend. With an ATR of 1.87, representing a 3.21% volatility, the stock has demonstrated relatively moderate price movements. Given the current fundamental data, including a market capitalization of 763.03M USD and a P/E ratio of 38.72, we can infer that the market has a relatively positive outlook on the companys future prospects.

Forecasting future performance, we can anticipate that IRMD will continue to benefit from its strong product portfolio and expanding customer base. As the demand for MRI-compatible medical devices grows, driven by the increasing adoption of MRI technology, Iradimed is poised to capitalize on this trend. With a forward P/E ratio of 34.13 and an RoE of 23.28, indicating a robust return on equity, we can expect the companys earnings to continue growing. Based on the technical and fundamental analysis, a potential price target for IRMD could be in the range of 65-70, representing a 10-15% increase from current levels, driven by the companys continued innovation and market expansion.

Additional Sources for IRMD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

IRMD Stock Overview

Market Cap in USD 772m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Equipment
IPO / Inception 2014-07-16

IRMD Stock Ratings

Growth Rating 79.4
Fundamental 84.3
Dividend Rating 5.08
Rel. Strength 43.6
Analysts 4.5 of 5
Fair Price Momentum 64.85 USD
Fair Price DCF 12.16 USD

IRMD Dividends

Dividend Yield 12m 1.12%
Yield on Cost 5y 2.87%
Annual Growth 5y -23.37%
Payout Consistency 81.4%
Payout Ratio 37.4%

IRMD Growth Ratios

Growth Correlation 3m 83.8%
Growth Correlation 12m 71.6%
Growth Correlation 5y 86.9%
CAGR 5y 22.14%
CAGR/Max DD 5y 0.45
Sharpe Ratio 12m -0.28
Alpha 24.26
Beta 0.922
Volatility 35.88%
Current Volume 109.4k
Average Volume 20d 61k
Stop Loss 57.2 (-3.6%)
What is the price of IRMD shares?
As of July 09, 2025, the stock is trading at USD 59.32 with a total of 109,352 shares traded.
Over the past week, the price has changed by -1.97%, over one month by -2.43%, over three months by +22.27% and over the past year by +36.68%.
Is Iradimed a good stock to buy?
Yes, based on ValueRay´s Fundamental Analyses, Iradimed (NASDAQ:IRMD) is currently (July 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 84.31 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IRMD is around 64.85 USD . This means that IRMD is currently overvalued and has a potential downside of 9.32%.
Is IRMD a buy, sell or hold?
Iradimed has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy IRMD.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecasts for IRMD share price target?
According to our own proprietary Forecast Model, IRMD Iradimed will be worth about 75.7 in July 2026. The stock is currently trading at 59.32. This means that the stock has a potential upside of +27.66%.
Issuer Target Up/Down from current
Wallstreet Target Price 71 19.7%
Analysts Target Price 71 19.7%
ValueRay Target Price 75.7 27.7%